Gossamer's CR3 agonist sensitizes pancreatic cancer to therapies

DISEASE CATEGORY: Cancer

INDICATION: Pancreatic cancer

Gossamer Bio Inc.'s CR3 agonist, GB1275, could sensitize pancreatic cancer to chemotherapy, radiation and immunotherapy. A team co-led by

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE